Innovent Biologics Inc - Company Profile
Powered by 
All the data and insights you need on Innovent Biologics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Innovent Biologics Inc Strategy Report
- Understand Innovent Biologics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Innovent Biologics Catalyst Calendar
Proactively evaluate Innovent Biologics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Innovent Biologics Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 15 Nov 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 02 Oct 2019 | Phase II Trial Completion | Cinda Biopharmaceutical Suzhou Co Ltd; Innovent Biologics Inc | 1801 | sintilimab | Oncology | Esophageal Cancer; Esophageal Squamous Cell Carcinoma (ESCC) | Clinical Trial Registry |
| 30 Sep 2019 | Phase I Trial Initiation | Innovent Biologics Inc | 1801 | IBI-110; sintilimab | Oncology | Adenocarcinoma Of The Gastroesophageal Junction; Advanced Malignancy; Gastric Cancer; Lymphoma; Solid Tumor; Squamous Non-Small Cell Lung Cancer | Clinical Trial Registry |
| 12 Aug 2019 | Phase II/III Trial Initiation | Innovent Biologics Inc | 1801 | tafolecimab | Metabolic Disorders | Homozygous Familial Hypercholesterolemia (HoFH) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer